322 filings
Page 4 of 17
8-K
6bxnggw k3iikepsha
4 Aug 20
Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis
7:50am
8-K
anbx fch8e2831
17 Jun 20
Other Events
4:46pm
8-K
nkzz6hgtuvfrwf0aonp
22 May 20
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
0611a1nol fq
7 May 20
Eloxx Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results and Provides Business Update
4:08pm
8-K
zk0a3y3
25 Mar 20
Eloxx Pharmaceuticals Provides Update on the Impact of Novel Coronavirus (COVID-19) on Phase 2 Clinical Trials in Cystic Fibrosis
9:10am
8-K/A
5g6k8 g6mwt2adp6n71
13 Mar 20
Departure of Directors or Certain Officers
4:01pm
8-K
smmik7emrdxtg 3cc0ae
5 Mar 20
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial and Operating Results and Provides Business Update
4:13pm
8-K
gl09smf3ky nax1pyr
26 Feb 20
Eloxx Strengthens its Commitment to Cystic Fibrosis Through Reallocating Resources
5:21pm
8-K
1gd061
14 Jan 20
Other Events
3:18pm
8-K
1etqfmkra3y 3o
5 Nov 19
Eloxx Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results and Provides Business Update
4:12pm
8-K
aws47ef6
7 Aug 19
Eloxx Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results and Provides Business Update
8:00am
8-K
sbdfjy
5 Aug 19
Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial for ELX-02 in Cystinosis
4:02pm
8-K
52nri287xsh472r mv7p
31 Jul 19
On track to report top line data from Phase 2 clinical trials for ELX-02 in cystic fibrosis and cystinosis
4:01pm
8-K
fa1yx7n 29kds
24 Jun 19
Eloxx Pharmaceuticals Announces Closing of Public Offering of Common Stock
4:16pm
8-K/A
j3vhzww6q3j8hq t8
21 Jun 19
Entry into a Material Definitive Agreement
5:10pm
8-K
7tirjjt
20 Jun 19
Eloxx Pharmaceuticals Announces Proposed
4:05pm
8-K
0zwaw1ibo 8qa85
29 May 19
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
kazgay4e7cy4oj3sd
9 May 19
Eloxx Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results and Provides Business Update
8:00am
8-K
nwt1 m2s7g7a8
8 Mar 19
Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial and Operating Results and Provides Business Update
7:33am
8-K
xlwdqzlxu2m jg8o
1 Feb 19
Entry into a Material Definitive Agreement
4:31pm